Alzheimer’s drug study yields positive results, say makers Eisai and Biogen

Sept 27 (Reuters) – An experimental Alzheimer’s drug made by Eisai Co Ltd (4523.T) and Biogen (BIIB.O) slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, they said on Tuesday, potentially a rare win in a field littered with failed drugs. […]

Click here to view original web page at www.reuters.com